Skip to main content

Influence of amiodarone treatment on inflammation during cardiopulmonary bypass


Cardiopulmonary bypass (CPB) induces a systemic inflammatory response (SIRS), which causes significant morbidity or even mortality. Amiodarone (Amio) has shown to reduce postoperative atrial fibrillation and also to reduce tumor necrosis factor alpha (TNF-α) production in vitro. Whether Amio reduces the post CPB SIRS is unknown.


The present study sought to investigate the anti-inflammatory properties of Amio after CABG using CPB.


Twenty-two patients undergoing elective CABG were randomly assigned to receive 600 mg Amio orally 7 days pre surgery daily and 45 mg/hour intravenously for 48 hours after initiation of CPB (10 patients, group 2) or placebo (12 patients, group 1). Two patients in group 2 were excluded due to withdrawn consent during the loading phase. The primary endpoint was the C-reactive protein (CRP) curve (AUC) up to 96 hours, and secondary endpoints were fibrinogen and WBC up to 96 hours and TNF-α and IL-6 curves up to 48 hours post surgery, respectively.


Baseline characteristics were not different between groups (age 61 ± 8 vs 62 ± 10 years, male 7/8 vs 10/12, EF 576 vs 53 ± 7%, SAPS II score 19 ± 3 vs 21 ± 8, CPB duration 78 ± 15 vs 79 ± 17 min, group 2 vs group 1, P = not significant). Amio did not reduce the postoperative CRP AUC when compared with placebo (1579 ± 260 vs 1397 ± 617, P = 0.44; Fig. 1). Furthermore, no significant differences in the AUCs of fibrinogen, WBC, TNF-α and IL-6 were observed. Length of ICU and hospital stay were not different between groups (2.4 ± 1.5 vs 2.7 ± 2.0 days, P = not significant and 9.0 ± 1.4 and 13.3 ± 7.1 days, P = not significant, group 2 vs group 1, respectively). There were no deaths in either group.

Figure 1

(abstract P82)


In this pilot study, there was no difference in the post CPB inflammatory reaction between Amio-treated and placebo-treated patients.

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Delle Karth, G., Buberl, A., Meyer, B. et al. Influence of amiodarone treatment on inflammation during cardiopulmonary bypass. Crit Care 9, P82 (2005).

Download citation


  • Placebo
  • Atrial Fibrillation
  • Fibrinogen
  • Amiodarone
  • Cardiopulmonary Bypass